Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL0217
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SL0217 is an autologous, nanobody-derived tandem dual-target chimeric antigen receptor T-cell (CAR-T) therapy designed to target both CD19 and CD22. Developed by Hebei Senlang Biotechnology in collaboration with Peking University People's Hospital, SL0217 utilizes unique alpaca-derived single-domain antibodies (VHHs) engineered into a single tandem CAR construct. This dual-targeting approach is designed to overcome antigen escape and treatment resistance, particularly in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) who have failed prior immunotherapies such as blinatumomab, inotuzumab ozogamicin, or single-target CAR-T therapies.
- Other names
- CD19/CD22 tandem CAR-TNanobody-based CD19/CD22 tandem dual CAR-TNanobody-derived CD19/CD22 tandem CAR-T
02
Targets
CD22 (Cluster of Differentiation 22)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on SL0217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL0217.